The most common adverse events are mild infections (such as upper respiratory tract infections) and injection site reactions (see Table 1), while the incidence of severe infections remains relatively low—around 2.5%–3.0%, which is lower than the infection rates typically seen with TNF-α inhibitors. This relatively lower infection risk makes secukinumab an attractive option for elderly EORA patients (Kunwar et al., 2016; Chabaud et al., 1999). Here, TNF is linked to infection.